scholarly journals A CLINICAL STUDY OF SECOND-LOOK OPERATIONS AIMED AT INTESTINAL CONTINUITY FOR OBSTRUCTIVE COLON CANCER MANAGED WITH THE HARTMANN OPERATION

2011 ◽  
Vol 72 (3) ◽  
pp. 560-566
Author(s):  
Naohito BEPPU ◽  
Hidenori YANAGI ◽  
Tsukasa AIHARA ◽  
Chiaki YASUI ◽  
Naoki YAMANAKA
Keyword(s):  
Colon Cancer ◽  
Clinical Study ◽  
Second Look ◽  
Intestinal Continuity ◽  
Hartmann Operation

scholarly journals Results of systematic second-look surgery plus hipec in perforated or pt4 colon cancer. Case series

2021 ◽  
Vol 62 ◽  
pp. 386-390
Author(s):  
Ángel Serrano del Moral ◽  
Estíbalitz Pérez Viejo ◽  
Israel Manzanedo Romero ◽  
Fernando Pereira Pérez
Keyword(s):  
Colon Cancer ◽  
Case Series ◽  
Cancer Case ◽  
Second Look

scholarly journals A Phase II Clinical Study of mFOLFOX6 /XELOX as Adjuvant Chemotherapy after Curative Resection of Stage III Colon Cancer: The FACOS Study

2016 ◽  
Vol 24 (1) ◽  
pp. 17-22 ◽  
Author(s):  
Keiichiro Ishibashi ◽  
Kensuke Kumamoto ◽  
Keiji Koda ◽  
Hiroyuki Kato ◽  
Genichi Nishimura ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Clinical Study ◽  
Adjuvant Chemotherapy ◽  
Phase Ii ◽  
Curative Resection ◽  
Stage Iii ◽  
Stage Iii Colon Cancer ◽  
Phase Ii Clinical Study

scholarly journals Survival of Peritoneal Recurrence of Colon Cancer by Second-look Operation based on Carcinoembryonic Antigen Evaluation

2003 ◽  
Vol 36 (6) ◽  
pp. 493-496 ◽  
Author(s):  
Haruhiko Naito ◽  
Tatuya Orimo ◽  
Nozomi Minagawa ◽  
Tomonori Hamada ◽  
Hirofumi Adachi ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Carcinoembryonic Antigen ◽  
Peritoneal Recurrence ◽  
Second Look ◽  
Second Look Operation

Short-Term Outcomes of the Australasian Randomized Clinical Study Comparing Laparoscopic and Conventional Open Surgical Treatments for Colon Cancer

2008 ◽  
Vol 248 (5) ◽  
pp. 728-738 ◽  
Author(s):  
Peter J. Hewett ◽  
Randall A. Allardyce ◽  
Philip F. Bagshaw ◽  
Christopher M. Frampton ◽  
Francis A. Frizelle ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Clinical Study ◽  
Short Term ◽  
Randomized Clinical Study ◽  
Surgical Treatments

scholarly journals Vitamin C administration by intravenous infusion increases tumour ascorbate content in patients with colon cancer: a clinical intervention study

2020 ◽  
Author(s):  
Gabi U Dachs ◽  
Jamish Gandhi ◽  
Christina Wohlrab ◽  
Anitra C Carr ◽  
Helen Morrin ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Clinical Study ◽  
Tumour Progression ◽  
Dehydroascorbic Acid ◽  
Normal Mucosa ◽  
Therapeutic Window ◽  
High Dose ◽  
Protein Markers ◽  
Tumour Biology ◽  
Plasma Ascorbate

Abstract Background: The use of high dose ascorbate infusions in cancer patients is widespread, but without evidence of efficacy. Several mechanisms whereby ascorbate could affect tumour progression have been proposed, including (i) the localised generation of cytotoxic quantities of H2O2, (ii) ascorbate-dependent activation of the 2-oxoglutarate-dependent dioxygenases that control the hypoxia-inducible factors (HIFs) and that are responsible for the demethylation of DNA and histones and (iii) increased oxidative stress induced by dehydroascorbic acid. We hypothesise that the dysfunctional vasculature of solid tumours results in compromised delivery of ascorbate to poorly perfused regions of the tumour and that this ascorbate deficit acts as an additional driver of the hypoxic response via upregulation of HIFs. Using a randomised ‘therapeutic window of opportunity’ clinical study we aimed to determine whether ascorbate infusions affected tumour ascorbate content and tumour biology.Methods: Patients with colon cancer were randomised to receive infusions of up to 1 g/kg ascorbate for four days before surgical resection (n=9) or to not receive infusions (n=6). Ascorbate was measured in plasma, erythrocytes, tumour and histologically normal mucosa at diagnostic colonoscopy and at surgery. Protein markers of tumour hypoxia or DNA damage were monitored in resected tissue.Results: Plasma ascorbate reached millimolar levels following infusion and returned to micromolar levels over 24 h. Pre-infusion plasma ascorbate increased from 38 ± 10 mM to 241 ± 33 mM (p<0.0001) over four days and erythrocyte ascorbate from 14 ± 15 mM to 2004 ± 814 mM (p<0.005). Tumour ascorbate increased from 15 ± 6 to 28 ± 6 mg/100g tissue (p<0.0001) and normal tissue from 14 ± 6 to 21 ± 4 mg/100g (p<0.001). A gradient of lower ascorbate was evident towards the tumour centre in both control and infusion samples. Lower expression of hypoxia-associated proteins was seen in post-infusion tumours compared with controls. There were no significant adverse events and quality of life was unaffected by ascorbate infusion.Conclusions: This is the first clinical study to demonstrate that tumour ascorbate levels increase following infusion, even in regions of poor diffusion, and that this could modify tumour biology. Trial registration: ANZCTR Trail ID ACTRN12615001277538

scholarly journals Number of Lymph Nodes in Primary Nodal Basin and a “Second Look” Protocol as Quality Indicators for Optimal Nodal Staging of Colon Cancer

2016 ◽  
Vol 141 (1) ◽  
pp. 125-130 ◽  
Author(s):  
Mikhail Lisovsky ◽  
Shannon N. Schutz ◽  
Michael G. Drage ◽  
Xiaoying Liu ◽  
Arief A. Suriawinata ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Lymph Nodes ◽  
Control Group ◽  
Nodal Staging ◽  
Pathologic Examination ◽  
Nodal Basin ◽  
Second Look ◽  
Group A ◽  
Node Count ◽  
Tumor Edge

Context.—Evaluation of 12 or more lymph nodes (LNs) is currently used as a quality indicator for adequacy of pathologic examination of colon cancer resections. Objective.—To evaluate the utility of a focused LN search in the immediate vicinity of the tumor and a “second look” protocol in improving LN staging in colon cancer. Design.—Lymph nodes were submitted separately from the primary nodal basin (PNB) and secondary nodal basin (SNB) defined as an area less than 5 cm away and an area greater than 5 cm away from the tumor edge, respectively, in 201 consecutive resections (2010–2013). One hundred sixty-eight consecutive tumors (2006–2009) were used as a control group. A second search was performed in all cases that were N0 after the first search. Results.—In cases that were N0 after the first search, 20.9 ± 10.8 LNs were collected from the PNB, compared to 8.5 ± 9.1 from the SNB. Positive LNs were found in N+ tumors in the PNB in all cases but in only 9% (4 of 46) of SNBs (P &lt; .001). A second search increased node count by an average of 10 additional LNs. In 5 of 114 cases (4.4%), N0 after the first search converted to N+ after a second search that yielded 1 to 4 positive LNs, all of which were in the PNB. Conclusions.—Emphasis on the number of LNs examined from the PNB and a “second look” protocol improve nodal staging.

Sign in / Sign up

Export Citation Format

Share Document